Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Chiasma, Inc. (NASDAQ: CHMA).

Full DD Report for CHMA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CHMA)

Chiasma Supports Acromegaly Awareness Day
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of pat...
Source: GlobeNewswire
Date: November, 01 2018 08:00
Chiasma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Mark Fitzpatrick, Chief Executive Officer and William Ludlam, MD, PhD,...
Source: GlobeNewswire
Date: August, 29 2018 16:05
Midday Gainers / Losers (08/20/2018)
Gainers:  SSC +66% . GRIN +48% . CMCM +20% . ALRN +19% . AGMH +15% . TLRY +15% . CRON +14% . SALM +13% . CHMA +13% . GWGH +12% . More news on: Seven Stars Cloud Group, Inc., Grindrod Shipping Holdings Ltd., Cheetah Mobile Inc., Stocks on the move, , ...
Source: SeekingAlpha
Date: August, 20 2018 12:54
Chiasma EPS in-line
Chiasma (NASDAQ: CHMA ): Q2 EPS of -$0.36 in-line. More news on: Chiasma, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:43
Chiasma Reports Second Quarter 2018 Results
Recent Highlights Include Completion of Enrollment of MPOWERED Phase 3 Trial and 50% Randomization in CHIASMA OPTIMAL Phase 3 Trial WALTHAM, Mass., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives o...
Source: GlobeNewswire
Date: August, 09 2018 16:05
Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
Chiasma Anticipates Trial Completion in Q4 2019 and Release of Top-line MPOWERED Data by Early 2020 WALTHAM, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious...
Source: GlobeNewswire
Date: July, 25 2018 16:05
Crinetics Pharmaceuticals Readies $80 Million IPO
Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise $80 million from the sale of its common stock in a U.S. IPO, according to an amended registration statement . The company is developing a pipeline of treatment candidates for rare endocrine disorders. CRNX has achieved pro...
Source: SeekingAlpha
Date: July, 10 2018 13:27
Crinetics Pharmaceuticals Begins IPO Process
Quick Take Crinetics Pharmaceuticals ( CRNX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . Crinetics is a clinical-stage pharmaceutical company that develops and manufactures pharmaceuticals for endocrine diseases and en...
Source: SeekingAlpha
Date: June, 28 2018 10:36
Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference
WALTHAM, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Drs. William Ludlam and Asi Haviv will present at the 12 th Acro...
Source: GlobeNewswire
Date: June, 18 2018 16:05
Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced it has achieved 50% patients randomized in its international Phase 3 c...
Source: GlobeNewswire
Date: June, 14 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-143.773.6853.863.68511,085
2018-12-133.853.733.853.618310,722
2018-12-123.803.823.843.689,642
2018-12-113.653.853.873.53583,834
2018-12-103.533.733.733.3524,090

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143272,97810.9805Cover
2018-12-131,1028,40613.1097Cover
2018-12-122,3015,00146.0108Short
2018-12-112,30150,5264.5541Cover
2018-12-071,0014,11424.3316Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CHMA.


About Chiasma, Inc. (NASDAQ: CHMA)

Logo for Chiasma, Inc. (NASDAQ: CHMA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $40,229,648 - 05/15/2018
  • Issue and Outstanding: 24,381,605 - 03/08/2018

 


Recent Filings from (NASDAQ: CHMA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 28 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 02 2018

 

 


Daily Technical Chart for (NASDAQ: CHMA)

Daily Technical Chart for (NASDAQ: CHMA)


Stay tuned for daily updates and more on (NASDAQ: CHMA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CHMA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CHMA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CHMA and does not buy, sell, or trade any shares of CHMA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/